Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer

This investigator-initiated study was supported by Coherus BioSciences, Inc., Redwood City, CA, USA. A. McBride serves on Speakers Bureaus for Coherus BioSciences, Inc., the study sponsor, and Merck. K. MacDonald and I. Abraham are equity shareholders of Matrix45, LLC, which was funded by Coherus BioSciences, Inc. to conduct this study. By company policy, they are prohibited from owning equity in client organizations (except through mutual funds or other independently administered collective investment instruments) or contracting independently with client organizations. Matrix45 provides similar services to those described in this article to other biopharmaceutical companies on a non-exclusivity basis. I. Abraham serves on a Speakers Bureau for Coherus BioSciences, Inc., the study sponsor. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

留言 (0)

沒有登入
gif